Les infections peuvent-elles aggraver la dégradation des ARNm ?
Certaines infections virales peuvent exacerber les symptômes liés à la dégradation des ARNm.
Infections viralesSymptômes
#4
Le mode de vie a-t-il un impact sur les risques ?
Un mode de vie sain peut réduire certains risques, mais ne prévient pas toutes les maladies.
Mode de viePrévention des maladies
#5
Les facteurs génétiques sont-ils déterminants ?
Oui, les mutations génétiques jouent un rôle clé dans la dégradation des ARNm non-sens.
Facteurs génétiquesMutations
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Dégradation des ARNm non-sens : Questions médicales les plus fréquentes",
"headline": "Dégradation des ARNm non-sens : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Dégradation des ARNm non-sens : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-07",
"dateModified": "2025-05-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Dégradation des ARNm non-sens"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Maturation post-transcriptionnelle des ARN",
"url": "https://questionsmedicales.fr/mesh/D012323",
"about": {
"@type": "MedicalCondition",
"name": "Maturation post-transcriptionnelle des ARN",
"code": {
"@type": "MedicalCode",
"code": "D012323",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.308.700"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Dégradation des ARNm non-sens",
"alternateName": "Nonsense Mediated mRNA Decay",
"code": {
"@type": "MedicalCode",
"code": "D059365",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Lynne E Maquat",
"url": "https://questionsmedicales.fr/author/Lynne%20E%20Maquat",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, USA."
}
},
{
"@type": "Person",
"name": "Luísa Romão",
"url": "https://questionsmedicales.fr/author/Lu%C3%ADsa%20Rom%C3%A3o",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisboa, Portugal. luisa.romao@insa.min-saude.pt."
}
},
{
"@type": "Person",
"name": "Fabrice Lejeune",
"url": "https://questionsmedicales.fr/author/Fabrice%20Lejeune",
"affiliation": {
"@type": "Organization",
"name": "Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France."
}
},
{
"@type": "Person",
"name": "Paulo J da Costa",
"url": "https://questionsmedicales.fr/author/Paulo%20J%20da%20Costa",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge, Lisboa, Portugal."
}
},
{
"@type": "Person",
"name": "Tatsuaki Kurosaki",
"url": "https://questionsmedicales.fr/author/Tatsuaki%20Kurosaki",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Angiotensin-converting enzyme 2-at the heart of the COVID-19 pandemic.",
"datePublished": "2023-02-02",
"url": "https://questionsmedicales.fr/article/36787743",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cell.2023.01.039"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of spike proteins on angiotensin converting enzyme 2 (ACE2).",
"datePublished": "2023-09-27",
"url": "https://questionsmedicales.fr/article/37769892",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.abb.2023.109769"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients.",
"datePublished": "2023-04-14",
"url": "https://questionsmedicales.fr/article/37060024",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40360-023-00667-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum levels of angiotensin-converting enzyme 2 in children with Kawasaki disease.",
"datePublished": "2022-11-07",
"url": "https://questionsmedicales.fr/article/36344782",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10238-022-00933-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Angiotensin-Converting Enzyme 2 (ACE2) Gene Polymorphism in Patients with Type 2 Diabetes (",
"datePublished": "2022-12-31",
"url": "https://questionsmedicales.fr/article/37274884",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.22092/ARI.2022.358736.2294"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Régulation de l'expression des gènes",
"item": "https://questionsmedicales.fr/mesh/D005786"
},
{
"@type": "ListItem",
"position": 4,
"name": "Maturation post-transcriptionnelle des ARN",
"item": "https://questionsmedicales.fr/mesh/D012323"
},
{
"@type": "ListItem",
"position": 5,
"name": "Dégradation des ARNm non-sens",
"item": "https://questionsmedicales.fr/mesh/D059365"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Dégradation des ARNm non-sens - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Dégradation des ARNm non-sens",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-10",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Dégradation des ARNm non-sens",
"description": "Comment diagnostiquer la dégradation des ARNm non-sens ?\nQuels tests sont utilisés pour évaluer la dégradation des ARNm ?\nQuels marqueurs biologiques indiquent une dégradation non-sens ?\nPeut-on détecter la dégradation des ARNm par imagerie ?\nQuel rôle joue la bioinformatique dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Angiotensin-Converting+Enzyme+2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Dégradation des ARNm non-sens",
"description": "Quels symptômes sont associés à la dégradation des ARNm non-sens ?\nLa dégradation des ARNm peut-elle causer des douleurs ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Angiotensin-Converting+Enzyme+2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Dégradation des ARNm non-sens",
"description": "Peut-on prévenir la dégradation des ARNm non-sens ?\nY a-t-il des mesures préventives recommandées ?\nL'alimentation joue-t-elle un rôle dans la prévention ?\nLes tests génétiques peuvent-ils prévenir des maladies ?\nLa sensibilisation est-elle importante pour la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Angiotensin-Converting+Enzyme+2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Dégradation des ARNm non-sens",
"description": "Quels traitements existent pour la dégradation des ARNm non-sens ?\nLes thérapies géniques sont-elles efficaces ?\nY a-t-il des médicaments spécifiques pour cette condition ?\nLes traitements sont-ils personnalisés ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Angiotensin-Converting+Enzyme+2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Dégradation des ARNm non-sens",
"description": "Quelles complications peuvent survenir ?\nLa dégradation des ARNm peut-elle entraîner des cancers ?\nY a-t-il des complications à long terme ?\nLes complications sont-elles réversibles ?\nComment les complications sont-elles traitées ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Angiotensin-Converting+Enzyme+2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Dégradation des ARNm non-sens",
"description": "Quels sont les facteurs de risque associés ?\nL'environnement influence-t-il la dégradation des ARNm ?\nLes infections peuvent-elles aggraver la dégradation des ARNm ?\nLe mode de vie a-t-il un impact sur les risques ?\nLes facteurs génétiques sont-ils déterminants ?",
"url": "https://questionsmedicales.fr/mesh/D059365?mesh_terms=Angiotensin-Converting+Enzyme+2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la dégradation des ARNm non-sens ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et l'analyse des ARNm par RT-PCR."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la dégradation des ARNm ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme le Northern blot et la séquençage d'ARN sont couramment utilisées."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques indiquent une dégradation non-sens ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'augmentation des ARNm contenant des mutations non-sens est un indicateur clé."
}
},
{
"@type": "Question",
"name": "Peut-on détecter la dégradation des ARNm par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne permet pas de détecter directement la dégradation des ARNm."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la bioinformatique dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bioinformatique aide à analyser les séquences d'ARN et à identifier les mutations non-sens."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à la dégradation des ARNm non-sens ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon la maladie sous-jacente, incluant fatigue et troubles neurologiques."
}
},
{
"@type": "Question",
"name": "La dégradation des ARNm peut-elle causer des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs peuvent survenir en raison de maladies génétiques associées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez les signes de dysfonctionnement organique ou neurologique."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains individus peuvent être asymptomatiques malgré la dégradation des ARNm."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps, selon la gravité de la condition sous-jacente."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la dégradation des ARNm non-sens ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives recommandées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques peuvent être utiles pour les familles à risque."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut soutenir la santé cellulaire, mais ne prévient pas directement."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des maladies ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent d'identifier les porteurs de mutations et de prendre des mesures."
}
},
{
"@type": "Question",
"name": "La sensibilisation est-elle importante pour la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sensibilisation aux maladies génétiques peut aider à un diagnostic précoce."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour la dégradation des ARNm non-sens ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies géniques et des médicaments ciblant les ARNm."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques sont-elles efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles montrent des résultats prometteurs, mais leur efficacité dépend de la maladie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments spécifiques pour cette condition ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les modulateurs d'ARN peuvent être utilisés pour cibler les ARNm."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires varient, incluant des réactions allergiques et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles neurologiques et des maladies dégénératives."
}
},
{
"@type": "Question",
"name": "La dégradation des ARNm peut-elle entraîner des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations peuvent augmenter le risque de cancers, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications chroniques peuvent affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles traitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement des complications dépend de leur nature et peut inclure des thérapies ciblées."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque associés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux de maladies génétiques et des mutations spécifiques."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il la dégradation des ARNm ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains facteurs environnementaux peuvent interagir avec des prédispositions génétiques."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la dégradation des ARNm ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent exacerber les symptômes liés à la dégradation des ARNm."
}
},
{
"@type": "Question",
"name": "Le mode de vie a-t-il un impact sur les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire certains risques, mais ne prévient pas toutes les maladies."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques sont-ils déterminants ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les mutations génétiques jouent un rôle clé dans la dégradation des ARNm non-sens."
}
}
]
}
]
}
Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA; Center for RNA Biology, University of Rochester, Rochester, NY 14642, USA.
Publications dans "Dégradation des ARNm non-sens" :
Department of Molecular Genetics, The Ohio State University, Columbus, OH 43210, USA; Center for RNA Biology, The Ohio State University, Columbus, OH 43210, USA. Electronic address: singh.734@osu.edu.
Publications dans "Dégradation des ARNm non-sens" :
ACE2 is the indispensable entry receptor for SARS-CoV and SARS-CoV-2. Because of the COVID-19 pandemic, it has become one of the most therapeutically targeted human molecules in biomedicine. ACE2 serv...
The Coronavirus Disease 2019 (COVID-19) pandemic was caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which enters host cells through interactions of its spike protein to Angiot...
Renin-angiotensin-aldosterone system (RAAS) is hypothesized to be in the center of COVID pathophysiology as the angiotensin converting enzyme 2 (ACE2) represents the main entrance of the virus, thus t...
A total of 40 healthy controls and 60 Egyptian patients suffering from chronic cardiovascular diseases were enrolled in this study. Patients were divided into 40 patients treated with ACEIs and 20 pat...
Assessment of serum ACE2 level in different groups showed a significant difference between ACEIs and healthy groups and ACEIs and ARBs group, while there was no difference between ARBs and healthy. Mu...
ACE2 levels varied between ACEIs and ARBs. It tends to be lower in ACEIs group and there is a strong positive association between ACE2 level and the female sex. This needs to be considered in Future s...
Retrospectively registered ClinicalTrials.gov ID: NCT05418361 (June 2022)....
Kawasaki disease (KD) has replaced rheumatic fever as the main cause of acquired heart disease in Japanese, American, and Chinese children. Polymorphisms in angiotensin-converting enzyme may be associ...
The increased levels of blood glucose associated with genetic and/or environmental risk factors have been known as Type 2 diabetes mellitus (T2D). T2D is categorized as a dangerous clinical syndrome f...
Rapid and cost-effective diagnostic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are a critical and valuable weapon for the coronavirus disease 2019 (COVID-19) pandemic respo...
In order to prevent COVID-19 from progressing, angiotensin-converting enzyme 2 (ACE2) binds to SARS-CoV-2 and prevents the virus from entering target cells. Several studies have found a correlation be...
We conducted a systematic review using PubMed, Embase, Cochrane Library, Scopus, Science Direct and Web of Science databases. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. ...
It was concluded that the ACE2 G8790A polymorphism was not associated with COVID-19 based on the data collected. Moreover, subgroup analyses stratified based on race proved that the ACE2 G allele show...
The findings indicated that the G allele of ACE2 G8790A was related to an enhanced risk of COVID-19 severity in Asians. One possible reason is that ACE2 G allele was associated with a COVID-19 cytokin...
Systemic sclerosis (SSc) is a disease with cardiovascular impairment and polymorphisms of the gene coding of angiotensin-converting-enzyme 2 (ACE2) may account for its development. Three single nucleo...
Genomic DNA was isolated from whole blood. Restriction-fragment-length polymorphism was used for genotyping of rs1978124, while detection of rs879922 and rs2285666 was based on TaqMan SNP Genotyping A...
81 SSc patients (60 women, 21 men) were enrolled. Allele C of rs879922 polymorphism was associated with significantly greater risk for development of AH (OR=2.5, p=0.018), but less frequent joint invo...
Polymorphisms of ACE2 may account for the development of AH and CVS disorders in SSc patients. Strong tendencies to more frequent occurrence of disease specific characteristics distinct to macrovascul...
The quick and advancing prevalence of the new coronavirus SARS-CoV-2 produced a global crisis surge with a profound impact on human health and worldwide economic constancy. The virus is known as one s...
The Angiotensin-Converting Enzyme 2 (ACE2) is the main receptor of the SARS-CoV-2. There is contradictory evidence on how the exposure to nicotine may module the concentration of soluble ACE2 (sACE2)....
Pooled analysis performed with data retrieved from two studies (n = 634 and n = 302). Geometric mean (GM) concentrations of sACE2, both total and relative to the total amount of protein in the sample,...
We observed a significant increase of 0.108‰ and 0.087 ng/μl in the relative and absolute salivary sACE2 GM concentrations, respectively, between the lowest and highest nicotine levels. Similar result...
Salivary nicotine concentration seems to be limitedly associated with the concentration of sACE2....